This week's roundup, in order: a fresh look at statins as a possible disease-modifying therapy for abdominal aortic aneurysm, a practical interpretation of the CREST-2 trial for asymptomatic carotid disease, a "risk-stacking" framework for why peripheral arterial disease outcomes are worsening in younger patients, an AI tool for recognizing chronic venous insufficiency skin changes from clinical photos, and a simple post-procedure flow measurement that predicts how long a dialysis access fix will last.

Aortic disease: Statins may be the closest thing we have to a disease-modifying drug for abdominal aortic aneurysm. Pooled registry, screening-cohort, and genetic evidence shows a dose-dependent association between statin intensity and slower aneurysm growth, with a favorable safety profile — though no dedicated randomized trial has tested this yet.
Skovbo JS, Lindholt JS. Statins in abdominal aortic aneurysm: a risk-benefit analysis. Curr Opin Cardiol. 2026. https://pubmed.ncbi.nlm.nih.gov/42647406/

Carotid disease: A commentary walks through how to interpret CREST-2 for asymptomatic carotid stenosis: adding carotid stenting to intensive contemporary medical management reduced the four-year risk of stroke or death versus medical management alone, while adding endarterectomy trended the same direction but did not reach statistical significance — a sign that modern medical therapy has narrowed, but not eliminated, the benefit of intervention.
Kelly P, McCabe J, De Borst GJ. Medical Treatment or Intervention for Asymptomatic Carotid Stenosis?: Interpreting CREST-2. Stroke. 2026;57(9):2952-2955. https://pubmed.ncbi.nlm.nih.gov/42495730/

Peripheral arterial disease: A proposed "risk-stacking" model argues that rising amputation rates in younger patients reflect the interaction of three layers — genetic risk via lipoprotein(a), cardiovascular-kidney-metabolic syndrome, and social determinants of health — and suggests one-time Lp(a) testing plus routine social-barrier screening to better target prevention.
Nudy M, Sinoway L, Aziz F, Brunner G. Risk stacking in peripheral artery disease (PAD): Integrating genetics, cardiometabolic disease and social determinants of health to explain worsening PAD outcomes. Int J Cardiol Cardiovasc Risk Prev. 2026;30:200684. https://pubmed.ncbi.nlm.nih.gov/42577030/

Venous disease: A deep learning pipeline trained on clinical photographs accurately distinguishes chronic venous insufficiency-related skin changes (lipodermatosclerosis, stasis dermatitis) from other skin conditions, with performance holding up on external multicenter data and a diverse public skin-tone dataset — a promising decision-support tool for telemedicine and primary care triage.
Kim KE, Lee Y, Kang H, et al. A deep learning framework for recognizing skin changes secondary to chronic venous insufficiency in clinical photographs: a multicentre validation study. Ann Med. 2026;58(1):2694142. https://pubmed.ncbi.nlm.nih.gov/42438416/

Dialysis access: In a recurrent-event cohort of hemodialysis patients, lower access blood flow measured immediately after endovascular intervention independently predicted a shorter time to the next required intervention — a simple, low-tech post-procedure check that could help target surveillance.
Shih HM, Lin CJ, Chuang SM, Chang KS, Wu CJ, Pan CF. Post-procedural access blood flow and repeat endovascular intervention in hemodialysis vascular access: a recurrent-event cohort study. Ren Fail. 2026;48(1):2697399. https://pubmed.ncbi.nlm.nih.gov/42635106/

All studies retrieved via PubMed.

Educational content only. Not medical advice. Consult your own clinical judgment and institutional protocols for any individual patient.

This episode covers deep venous valve repair patient selection, pelvic venous disorder outcomes, and iliac stent patency risk factors in venous disease; a new blood-based prognostic score after type B aortic dissection repair; a challenge to stenosis-only carotid risk stratification; medication adherence's real impact after leg artery procedures; and a bioengineered vessel outperforming the standard fistula for dialysis access.

Full abstracts and references for every paper discussed are in the show notes: https://claude.ai/code/artifact/aed30162-a301-4682-9f7b-6b473a78747c

Educational content only. Not medical advice. Consult your own clinical judgment and institutional protocols for any individual patient.

Two tracks, seven studies, straight from PubMed this week.

Venous disease: A 139,000-patient cohort linking GLP-1 receptor agonists to roughly half the risk of DVT and PE in obese patients with chronic venous insufficiency — plus a practice-challenging look at anticoagulation in isolated distal DVT, where routine treatment showed no PE benefit and higher mortality.

Vascular surgery: Why stenosis percentage alone may be misleading you in symptomatic carotid disease, what German registry data says about open AAA volume thresholds, how TADV circuits actually mature in no-option CLTI, why medication nonadherence is quietly driving amputations after revascularization, and what obesity really does — and doesn't do — to outcomes after lower extremity bypass.

Every study cited with its DOI. The numbers as the authors reported them, and one line on what to do differently in clinic.

Educational content only. Not medical advice. Consult your own clinical judgment and institutional protocols for any individual patient.

Current Vascular Roadmap is a daily briefing that pulls the newest vascular surgery and venous disease literature straight from PubMed — filtered to the journals worth your time, distilled into what actually changes practice, delivered in under 30 minutes.

Two tracks, every episode. Venous disease: superficial and deep venous disease, May-Thurner syndrome, pelvic congestion, acute DVT, post-thrombotic obstruction, and varicosity. And broader vascular surgery: aortic, carotid, and peripheral arterial disease, from EVAR to CLTI to claudication.

No filler, no recycled takes — just the studies that matter, the numbers as the authors actually reported them, and the one line that tells you what to do differently in clinic tomorrow.

Built for vascular surgeons, by a vascular surgeon. New episodes drop every morning.